NCT00663429 2011-08-31
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
Callisto Pharmaceuticals
Phase 2 Completed
Clinical Trials
4 trialsNCT00086216 2007-12-21
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
Callisto Pharmaceuticals
Phase 1/2 Completed
NCT00388063 2007-12-21
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Callisto Pharmaceuticals
Phase 2 Completed
NCT00214838 2006-12-05
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
Callisto Pharmaceuticals
Phase 1/2 Unknown